Stručni rad - Pismo uredniku
Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism
British Journal of Clinical Pharmacology, 88 (2022), 10; 4654-4656. https://doi.org/10.1111/bcp.15451


Citirajte ovaj rad

Trkulja, V. (2022). Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism. British Journal of Clinical Pharmacology, 88. (10), 4654-4656. doi: 10.1111/bcp.15451

Trkulja, Vladimir. "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism." British Journal of Clinical Pharmacology, vol. 88, br. 10, 2022, str. 4654-4656. https://doi.org/10.1111/bcp.15451

Trkulja, Vladimir. "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism." British Journal of Clinical Pharmacology 88, br. 10 (2022): 4654-4656. https://doi.org/10.1111/bcp.15451

Trkulja, V. (2022) 'Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism', British Journal of Clinical Pharmacology, 88(10), str. 4654-4656. doi: 10.1111/bcp.15451

Trkulja V. Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism. British Journal of Clinical Pharmacology [Internet]. 13.07.2022. [pristupljeno 29.11.2024.];88(10):4654-4656. doi: 10.1111/bcp.15451

V. Trkulja, "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism", British Journal of Clinical Pharmacology, vol. 88, br. 10, str. 4654-4656, Srpanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:220170. [Citirano: 29.11.2024.]